The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Biomarkers in ITP: understanding a patient’s immune phenotype and guiding therapeutic selection
Hanny Al-Samkari, MD, Massachusetts General Hospital, Boston, MA, comments on the challenges of identifying biomarkers in immune thrombocytopenia (ITP) to understand a patient’s underlying immune phenotype and guide therapeutic selection. Dr Al-Samkari notes that while some studies have shown potential correlations between certain biomarkers and treatment response, these findings are not yet widely applicable in clinical practice. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
